AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06643546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: model simulation training
Description: theoretical breastfeeding training and model simulation training accompanied by scenarios
Study NCT06643546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: live-simulation
Description: theoretical breastfeeding training and live simulation training with scenarios
Study NCT05406453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Genome Sequencing testing
Description: Whole Genome Sequencing testing, community-based contact tracing
Study NCT04457154 — intervention group
Intervention type: DEVICE
Intervention: Inspire Upper Airway Stimulation System
Description: Implant of the Inspire Upper Airway Stimulation System
Study NCT06113198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Description: 3 doses of rMenB+OMV NZ vaccine administered intramuscularly on Day 1, Day 61, and any day between Day 241 - Day 391.
Study NCT04846699 — intervention group
Intervention type: PROCEDURE
Intervention: per-cutaneous stone extraction
Description: percutaneous nephrolithotripsy for renal stones by different renal access
Study NCT05756621 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: Dual anti-glutamatergic therapy (DUAL) intervention group: patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight > 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight \< 50 kg), followed by gradual reduction according to clinical evolution.
Study NCT05756621 — intervention group
Intervention type: DRUG
Intervention: Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel
Description: Any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs Ketamine and Perampanel
Study NCT06200779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test
Description: Described in Arms section
Study NCT06200779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®)
Description: Described in Arms section
Study NCT06200779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days
Description: Administered to patients randomized to Intervention group and with H. pylori clarithromycin-sensitive strain
Study NCT06200779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI, amoxicillin 1g and levofloxacin 250 mg, twice daily, for 10 days
Description: Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-sensitive strain
Study NCT06200779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth quadruple therapy (Pylera®) for 10 days
Description: Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-resistant strain
Study NCT06439407 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SAT-014(Software as Medical Device)
Description: SAT-014(Software as Medical Device) + maintain previous treatment
Study NCT06439407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAT-014(Software as Medical Device)
Description: SAT-014(Software as Medical Device) + maintain previous treatment
Study NCT06651970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acalabrutinib
Description: Acalabrutinib Monotherapy
Study NCT06651970 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Investigator's choice of treatment
Description: control arm treatment type will be defined by the PI prior to randomisation
Study NCT04816903 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gyni
Description: Vaginal discharge collection
Study NCT05671887 — intervention group
Intervention type: PROCEDURE
Intervention: Double Lung Transplantation
Description: To evaluate outcomes among patients who undergo lung transplantation for treatment of a select group of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.
Study NCT06367972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Consolidation Therapy
Description: Participants may receive radiation therapy. The choice of LCT and radiation therapy regimen will be determined by a multidisciplinary team including the study doctor.
Study NCT06367972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Next-line Systemic Therapy
Description: The specific next-line systemic therapy will be determined by your doctor.
Study NCT05940324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is an FDA-approved dissociative anesthetic.
Study NCT05940324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine is an FDA-approved dissociative anesthetic.
Study NCT05940324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Pill
Description: Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)
Study NCT05940324 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: An oral inactive placebo pill will be administered to preserve the blinded nature of the study.
Study NCT06010836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Script guided conversation
Description: Patients getting script guided intervention of 3 domains in the preoperative period
Study NCT05563207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional Chinese medicine health education standard path
Description: Both groups of patients were given routine treatment, and were intervened by the same batch of nursing staff.During chemotherapy, the patient's condition was closely observed, patiently listened to the patient's chief complaint, answered their questions, and instructed the patient to follow the doctor's instructions to prevent complications such as infection and bleeding.
Study NCT05563207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional Chinese medicine health education standard path
Description: Both groups of patients were given routine treatment, and were intervened by the same batch of nursing staff.During chemotherapy, the patient's condition was closely observed, patiently listened to the patient's chief complaint, answered their questions, and instructed the patient to follow the doctor's instructions to prevent complications such as infection and bleeding.
Study NCT05563207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The contents of the health intervention mainly included:Graphic and text education
Description: When the patient was admitted to the hospital, the responsible nurse had a comprehensive understanding of the patient's disease cognition and psychological state, and based on this, an individualized intervention plan was formulated. With the help of publicity boards, brochures and other forms of pictures and texts, to popularize the knowledge and precautions of disease treatment for patients
Study NCT05563207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The contents of the health intervention mainly included:Language education
Description: adopt one-to-one method to inform patients of the principles, effects and precautions of chemotherapy, eliminate patients' misunderstandings, and repeat language education for many times during the treatment process to strengthen patients' memory
Study NCT05563207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The contents of the health intervention mainly included:Psychological education
Description: guide patients to express their own emotions, according to the patient's personality, cultural background, etc., after communicating with family members and negotiating, selectively inform the patient's actual condition
Study NCT05563207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The contents of the health intervention mainly included:Dietary education
Description: instruct patients to follow the principles of light, easy to digest and balanced nutrition
Study NCT05563207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The contents of the health intervention mainly included:Complication education
Description: Actively inform patients about complications in advance, and guide their prevention methods, such as increasing water intake, avoiding activities of affected limbs after chemotherapy, etc. Patients with vomiting, hair loss and other adverse reactions are prone to negative emotions such as anxiety and depression , timely take corresponding measures and appease the patient, inform them that it is a normal phenomenon, and guide them to maintain a good attitude.
Study NCT05698316 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of both retrospective and prospective data collection in 3 visits.
Description: 3 clinic visits with multimodal imaging done at least at 6 months interval between 2 visits and meet the inclusion and exclusion criteria. Those with one visit remaining to complete 2 years, images will be acquired prospectively. In addition to the images, routine demographic data (age and sex) and available visual acuity (VA) (BCVA if possible, VA with Pinhole or VA with patient's glasses) will be collected. Multimodal imaging includes mandated macular OCT with or without enhanced depth imaging and infrared imaging. Fundus autofluorescence (AF) and multicolor imaging are optional. All imaging must be done on Heidelberg Spectralis system.
Study NCT06333158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholesfytol NG
Description: 3 capsules a day with dinner.
Study NCT04288193 — intervention group
Intervention type: DRUG
Intervention: Recommendation to Deprescribe
Description: Recommendation to Deprescribe
Study NCT06333158 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules a day with dinner
Study NCT06664853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate
Description: Dexamethasone Sodium Phosphate encapsulated in autologous erythrocytes and administered via intravenous (IV) infusion
Study NCT05465174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05465174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovorafenib
Description: Given orally
Study NCT06672666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemp Derived Cannabidiol Extract
Description: Participants will be given the study drug in a titrated method of 50-150mgs per day for 4 weeks
Study NCT06672666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Partcipants will be given placebo substance to be taken with titrated instructions that mimic IP dispensing method daily for 4 weeks
Study NCT06671262 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Target the primary tumor region with a single dose of 8Gy, or deliver a dose of 3Gy to the axillary lymph nodes, administered once a day for three consecutive days.
Study NCT06671262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immuno-chemotherapy
Description: Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by epirubicin, cyclophosphamide, and toripalimab for another four cycles.
Study NCT06671262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immuno-chemotherapy
Description: Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by epirubicin, cyclophosphamide, and toripalimab for another four cycles.
Study NCT06545825 — intervention group
Intervention type: OTHER
Intervention: Standard enteral nutrition
Description: Enteral nutrition will be given with standard isocaloric mixtures. Mixture volume calculation will be performed after indirect calorimetry, adjusted for daily nitrogen loss.
Study NCT05595499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05595499 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05595499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Given PO
Study NCT05595499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05595499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05595499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05595499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05595499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05120349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease recurrence, unacceptable toxicity or other discontinuation criteria are met.
Study NCT05120349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.
Study NCT05566769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMOSDCopilot smartphone application
Description: NMOSDCopilot includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to pain, fatigue, quality of life, bladder and bowel dysfunction, depression
Study NCT05377814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Description: Participants are asked to choose from a list of strategies for increasing physical activity
Study NCT05197270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-150 IVT
Description: 4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept
Study NCT05197270 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept IVT
Description: Commercially available Active Comparator Other Name: Eylea
Study NCT05786196 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ab-interno canaloplasty utilizing the iTrack Advance device
Description: 360 degree microcatheterization and viscodilation of Schlemm's canal
Study NCT05786196 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ab-interno canaloplasty utilizing the OMNI Surgical System
Description: 360 degree microcatheterization and viscodilation of Schlemm's canal
Study NCT06538350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Consultation
Description: Telemedicine intervention will be delivered via Zoom and Video WhatsApp platforms via a secure internet connection.
Study NCT06538350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-Face Consultation
Description: Face-to-Face consultation according to the standard of care.
Study NCT05676450 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cell-free DNA
Description: Given by IV (vein)
Study NCT04938843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: F. prausnitzii and D. piger
Description: Dietary supplementation with capsules containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
Study NCT04938843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary supplementation with placebo capsules identical to those containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
Study NCT06417788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant placement
Description: Dental implant placement guided by Navident® (ClaroNav Inc., Toronto, Canada)
Study NCT06417788 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static guided implant placement
Description: Dental implant placement guided by a stereolithographic pilot drill guide.
Study NCT05544344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy ReStart
Description: In addition to receiving mental health services as usual, subjects receive services from health coaches over a four-month period to assist them in creating a Restart plan and attaining related life goals.
Study NCT05544344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Subjects receive mental health services as usual.
Study NCT06220253 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: vaginal hysterectomy by bipolar vessels sealing
Description: The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be coagulated and cut by a bipolar vessel sealing instrument
Study NCT06220253 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: vaginal hysterectomy by traditional technique
Description: The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be sutured by absorbable threads
Study NCT06067139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHUTi
Description: Each core includes a variety of interactive features, such as animations, vignettes, myth and reality buttons that reveal common misperceptions and facts about sleep, learn more buttons that provide in-depth information about a topic, and quizzes. All cores follow a similar structure with objectives, main content, homework, and review. Participants are free to revisit cores as many times as they like.
Study NCT06067139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: The PE website will present content in a simple, static form, without interactive components; and all content on the website will be provided at once, rather than in modules that unlock over time. The PE website will also not provide personalized or individually tailored treatment recommendations.
Study NCT06398574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real dry needling
Description: With the subject lying supine, a dry needling technique will be applied to the infraspinatus muscle. First, the most hyperalgesic point in the muscle will be located. Subsequently, Hong's fast-in and fast-out technique will be applied. Ten incisions will be made
Study NCT06398574 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham dry needling
Description: With the subject lying supine, a sham dry needling technique will be applied to the infraspinatus muscle. First, the most hyperalgesic point in the muscle will be located. Subsequently, Hong's fast-in and fast-out technique will be applied. Ten incisions will be made, simulating the real technique
Study NCT06133270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0560-0004
Description: NNC0560-0004, Oral administration (taken through the mouth)
Study NCT06133270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0560-0004)
Description: Placebo matching NNC0560-0004, Oral administration (taken through the mouth)
Study NCT05313958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5mg/㎡/day d1-5 in 2 hours, before the use of Cytarabine
Study NCT05313958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5ug/kg/day d0-5,if Peripheral blood leukocytes\<20,000/ul
Study NCT05313958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2g/㎡/day d1-5 in 4 hours, after the use of Cladribine
Study NCT05313958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
Study NCT05313958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
Study NCT05313958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 200mg/m2/day was taken orally until molecular biology remission for 2 years
Study NCT05601843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: TENS pads will be applied in a frame pattern around the area of maximal pain, as pointed out by the patient. The pads will be no more than 6 cm and no less than 3 cm away from the subjective area of maximal pain. The frequency of the TENS machine will be set to 100 Hz and the patient will be instructed on how to increase and decrease the amplitude based on their comfort. The patient will also be instructed on how to turn off the machine if they wish for any reason. Research assistants will be standing by during the intervention period to intervene if the patient requires assistance with the device.
Study NCT06706726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy
Description: sentinel lymph node biopsy during the management of breast cancer